News Archives | Page 6 of 7

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

ST. LOUIS, MO, February 22, 2021 /PRNewswire/ – Wugen Inc., a biotechnology company developing novel, universal allogeneic cellular therapies, today announced that it has entered into an exclusive license agreement…

22 February

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

ST. LOUIS, February 22, 2021 – Wugen Inc., a biotechnology company developing novel, universal allogeneic off-the-shelf cell therapies, today announced the appointment of Jan Davidson M.D., Ph.D., as the company’s…

22 February

Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer

Biospace, Kate Goodwin, January 2021

26 January

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Cancer Discovery, Berrien-Elliott et al, December 2020

06 December

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

ST. LOUIS, Nov. 19, 2020 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ryan Sullivan, Ph.D., as Vice President and Head of…

19 November

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, Gang et al, November 2020

01 November

Memory-like natural killer cells for cancer immunotherapy

Seminars in Hematology, Gang et al, November 2020

01 November

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

01 December

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

ST. LOUIS, April 30, 2019 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., as Vice President of Finance…

30 April

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

ST. LOUIS, March 26, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as Vice President of Research and…

26 March

ARCHIVE

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company’s Global NK and T cell Clinical Programs

Wugen Ramps Up Off-the-Shelf Gene Therapies to Fight Cancer

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Memory-like natural killer cells for cancer immunotherapy

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

ST. LOUIS

SAN DIEGO

SOCIAL